We evaluated multiple NCBI datasets and found that PI4KA is significantly associated with metastatic disease, and in therapy resistance disease its expression is associated with neuroendocrine phenotype (Supplementary Fig. 3). This evidence concerns the gene PI4KA and metastatic neoplasm.